Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 200Active not recruiting 77Terminated 49Recruiting 49Unknown 22Withdrawn 18Not yet recruiting 9No longer available 3Enrolling by invitation 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma 1HTLV-I Infections 1

Interventions

daratumumab 2Dexamethasone 2vactosertib 1selinexor 1pomalidomide 1mirdametinib 1fludarabine phosphate 1carfilzomib 1aldesleukin 1Specimen Handling 1Sirolimus 1Melphalan 1Lenalidomide 1Interleukin-2 1IL32 protein, human 1Cyclophosphamide 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Multiple Myeloma × Lenalidomide × Clear all
NCT06348147 2026-05-04

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

UNC Lineberger Comprehensive Cancer Center

Phase 2 Suspended
39 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡